Let's be reasonable

WASHINGTON - A second special panel of ad hoc advisors to the NIH last week managed to reach some agreement that CRADA policy should be reoriented away from "reasonable pricing" and toward "reasonable access" to drugs created with NIH involvement.

The panel members, representing consumer groups, patient advocates, industry representatives and NIH staff, also were able to agree that the scope of activities covered by such provisions should be limited...